TY - JOUR
T1 - Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis
AU - Kumar, Anurag
AU - Kumar, Vikas
AU - Arora, Mohit
AU - Kumar, Manish
AU - Ammalli, Prajwal
AU - Thakur, Bhaskar
AU - Prasad, Jitender
AU - Kumari, Sarita
AU - Sharma, Mehar Chand
AU - Kale, Shashank Sharad
AU - Chauhan, Shyam S.
N1 - Publisher Copyright:
© 2022 Portland Press Ltd. All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - Prothymosin-α (PTMA), a nuclear protein, is strikingly associated with unfavorable clinical outcomes in many cancers. However, no information about its clinical relevance in glioma was available. Therefore in the present study, we evaluated the prognostic utility of this protein in a cohort of 81 glioma patients. The PTMA expression was assessed by immunohistochemical analysis, quantitative PCR, and Western blotting. Furthermore, the association of PTMA with clinicopathological features and molecular alterations were assessed in the patient cohort and validated in multiomics datasets, The Cancer Genome Atlas (TCGA; n=667) and Chinese Glioma Genome Atlas (CGGA; n=1013). We observed an increase in PTMA expression with increasing histological grades of this malignancy. PTMA immunostaining also displayed a strong positive association with the MIB-1 index. Univariate analysis revealed a superior prognostic value of PTMA to predict overall survival (OS) as compared with the routinely used markers (p53, isocitrate dehydrogenase (IDH) 1 (IDH1), α-thalassemia/intellectual disability syndrome X-linked (ATRX), and Ki-67). Interestingly, in Cox regression analysis it emerged as an independent predictor of OS (hazard ratio (HR) = 13.71, 95% CI = 5.96-31.52, P<0.0001). Thus, our results demonstrate the potential prognostic utility of PTMA in glioma which may prove useful in the management of this deadly malignancy.
AB - Prothymosin-α (PTMA), a nuclear protein, is strikingly associated with unfavorable clinical outcomes in many cancers. However, no information about its clinical relevance in glioma was available. Therefore in the present study, we evaluated the prognostic utility of this protein in a cohort of 81 glioma patients. The PTMA expression was assessed by immunohistochemical analysis, quantitative PCR, and Western blotting. Furthermore, the association of PTMA with clinicopathological features and molecular alterations were assessed in the patient cohort and validated in multiomics datasets, The Cancer Genome Atlas (TCGA; n=667) and Chinese Glioma Genome Atlas (CGGA; n=1013). We observed an increase in PTMA expression with increasing histological grades of this malignancy. PTMA immunostaining also displayed a strong positive association with the MIB-1 index. Univariate analysis revealed a superior prognostic value of PTMA to predict overall survival (OS) as compared with the routinely used markers (p53, isocitrate dehydrogenase (IDH) 1 (IDH1), α-thalassemia/intellectual disability syndrome X-linked (ATRX), and Ki-67). Interestingly, in Cox regression analysis it emerged as an independent predictor of OS (hazard ratio (HR) = 13.71, 95% CI = 5.96-31.52, P<0.0001). Thus, our results demonstrate the potential prognostic utility of PTMA in glioma which may prove useful in the management of this deadly malignancy.
UR - http://www.scopus.com/inward/record.url?scp=85128798190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128798190&partnerID=8YFLogxK
U2 - 10.1042/BSR20212685
DO - 10.1042/BSR20212685
M3 - Article
C2 - 35297481
AN - SCOPUS:85128798190
SN - 0144-8463
VL - 42
JO - Bioscience reports
JF - Bioscience reports
IS - 4
M1 - BSR20212685
ER -